CellSource Co., Ltd.
Research CellSource Co., Ltd. (4880.T) on Bullrun: market cap JPY 6.25B, P/E 63.4, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4880.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 6.25B
- P/E63.4
- Dividend yield1.6%
- Financial periodFY2025
- RevenueJPY 3.71B
- Revenue growth-14.8%
- Net incomeJPY 10.66M
- Free cash flowJPY 282.98M
- Gross margin56.2%
Valuation Snapshot
latest market cap is JPY 6.25B; P/E is 63.4; dividend yield is 1.6%.
Peer valuation comparison
Latest P/E is 63.38x versus a Healthcare sector median of 21.8x (190.8% above).
Latest dividend yield is 1.6% versus a Healthcare sector median of 2.41% (33.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 3.71B | JPY 10.66M | JPY 282.98M | 56.2% | 0.54 | JPY 4.71B | JPY 56.72M | JPY 6.02B |
| FY2024 | JPY 4.36B | JPY 237.94M | JPY 52.04M | 55.5% | 11.96 | JPY 4.32B | JPY 77.29M | JPY 6.04B |
| FY2023 | JPY 4.51B | JPY 923.14M | JPY 487.69M | 70.6% | 47.93 | JPY 4.78B | JPY 97.54M | JPY 6.20B |
| FY2022 | JPY 4.27B | JPY 1.02B | JPY 748.44M | 71.7% | 52.98 | JPY 3.12B | JPY 0 | JPY 3.79B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 6.25B | 63.4 | 1.6% | 5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 5 JPY, yield 1.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 5 JPY |
| FY2024 | 5 JPY |
| FY2023 | 20 JPY |
About CellSource Co., Ltd.
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CellSource Co., Ltd.'s market cap?
CellSource Co., Ltd.'s market capitalization is JPY 6.25B.
What is CellSource Co., Ltd.'s P/E ratio?
CellSource Co., Ltd.'s price-to-earnings (P/E) ratio is 63.4.
Does CellSource Co., Ltd. pay a dividend?
CellSource Co., Ltd. has a dividend yield of 1.6%.
What does CellSource Co., Ltd. do?
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.